|
|
Post by mnholdem on Jun 4, 2016 21:10:48 GMT -5
The "new" is certainly correct, but the "more expensive" remains to be seen, both in the U.S. and eventually in European markets.
|
|
|
|
Post by capnbob on Jun 4, 2016 21:19:49 GMT -5
I thought I heard at one of the more recent conference calls, MNKD specifically stated that they had no plans to go outside the US at present. All their energy was focused on the US market.
|
|
|
|
Post by victoria on Jun 5, 2016 17:22:28 GMT -5
/start speculation: Massive speculation by me, but perhaps Dr Castagnas tweet foreshadows commencement of trials in the eu or uk. That would be a way for uk people to use afrezza sooner rather than later. Presume we would need a partner for that but.. may be we will have a partner. /end speculation
|
|
|
|
Post by anderson on Jun 5, 2016 19:12:57 GMT -5
With the Brexit vote 23June16 we will soon know if the UK is going it along as well. How does that change things for drug approval in the UK and the EU?
|
|
|
|
Post by victoria on Jun 6, 2016 3:02:59 GMT -5
With the Brexit vote 23June16 we will soon know if the UK is going it along as well. How does that change things for drug approval in the UK and the EU? Brexit would have no immediate effect but would mean that over a period of a year or two the UK would unwind it's various legal agreements and treaties with the rest of the EU which would be a complex task (eg what rights would foreign eu nationals have in the independent UK and vice versa?). So no immediate change to drug approval process on the morning of 24th June, but within a reasonably short time the UK and EU would have to decide whether to have any mutual recognition of drug approvals or not, and then there could be changes. On the other hand it would mean the UK would then be free eg to decide to recognise both EU and FDA approvals, or neither, if it wanted. The "leave" campaign just pulled into the lead as of a few days ago in the polls. |
|
